Stockscreener 앱 받기
16.51
1.29%
0.21
시간 외 거래:
16.27
-0.24
-1.45%
전일 마감가:
$16.30
열려 있는:
$16.37
하루 거래량:
525.02K
Relative Volume:
0.43
시가총액:
$1.84B
수익:
$577.74M
순이익/손실:
$-149.78M
주가수익비율:
-11.79
EPS:
-1.4
순현금흐름:
$-78.21M
1주 성능:
-0.48%
1개월 성능:
-0.60%
6개월 성능:
-38.90%
1년 성능:
-12.04%
1일 변동 폭
$16.35
$16.61
1주일 범위
$15.90
$16.81
52주 변동 폭
$14.17
$34.13
Novocure Ltd Stock (NVCR) Company Profile
명칭
Novocure Ltd
전화
44 (0)15 3475 6700
주소
NO. 4 THE FORUM, ST. HELIER
NVCR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
16.51 | 1.82B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
125.83 | 218.75B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
107.76 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
400.93 | 151.01B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.01 | 117.43B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
76.91 | 44.76B | 5.54B | 4.18B | 623.10M | 7.00 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-08 | 개시 | Ladenburg Thalmann | Buy |
| 2024-12-02 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2024-10-16 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | 재개 | JP Morgan | Neutral |
| 2023-08-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | 개시 | SVB Securities | Outperform |
| 2023-07-31 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2023-06-07 | 업그레이드 | Wedbush | Underperform → Neutral |
| 2023-05-16 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-01-06 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | 재확인 | H.C. Wainwright | Buy |
| 2022-11-29 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2022-05-16 | 개시 | H.C. Wainwright | Buy |
| 2022-02-08 | 개시 | Loop Capital | Buy |
| 2022-02-02 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-20 | 업그레이드 | Truist | Hold → Buy |
| 2022-01-03 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-07-01 | 다운그레이드 | Mizuho | Buy → Neutral |
| 2021-04-14 | 다운그레이드 | Wedbush | Neutral → Underperform |
| 2021-01-25 | 재확인 | Piper Sandler | Overweight |
| 2020-09-23 | 개시 | Northland Capital | Outperform |
| 2020-09-18 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | 다운그레이드 | Truist | Buy → Hold |
| 2020-06-01 | 재개 | Oppenheimer | Perform |
| 2020-05-01 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-04-09 | 다운그레이드 | Evercore ISI | In-line → Underperform |
| 2020-03-05 | 업그레이드 | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2019-07-29 | 업그레이드 | SunTrust | Hold → Buy |
| 2019-07-26 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2019-07-26 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2019-03-20 | 개시 | SunTrust | Hold |
| 2018-11-02 | 다운그레이드 | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | 개시 | Evercore ISI | Outperform |
| 2018-04-18 | 재확인 | Mizuho | Buy |
| 2018-02-23 | 재확인 | Mizuho | Buy |
| 2017-05-24 | 업그레이드 | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | 재확인 | Wedbush | Outperform |
| 2016-01-19 | 개시 | Barclays | Underweight |
| 2015-12-02 | 개시 | Deutsche Bank | Hold |
모두보기
Novocure Ltd 주식(NVCR)의 최신 뉴스
What analysts say about NovoCure Limited stockBreakthrough wealth creation - Autocar Professional
What drives NovoCure Limited stock priceRobust investment performance - jammulinksnews.com
Is NovoCure Limited a good long term investmentUnmatched market gains - jammulinksnews.com
M&T Bank Corp Sells 1,750 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
NovoCure Limited Stock Analysis and ForecastExplosive portfolio gains - jammulinksnews.com
How NovoCure Limited stock performs during market volatilityBreakout Level Watch - Newser
What makes NovoCure Limited stock price move sharplyFree Stock Market Group - Newser
Why NovoCure Limited stock attracts strong analyst attentionFast Growing Stocks - Newser
NovoCure (NASDAQ:NVCR) shareholders are up 4.2% this past week, but still in the red over the last three years - simplywall.st
Teacher Retirement System of Texas Buys 3,123 Shares of NovoCure Limited (NASDAQ:NVCR) - Defense World
Most Volatile Stocks in the US (July 2025) - Investing.com
NovoCure Ltd Stock Price Falls 3.41% Amid Analyst Predictions of 81.88% Upside - AInvest
LADENBURG THALM/SH SH Initiates Coverage on NovoCure (NASDAQ:NVCR) - Defense World
NovoCure stock initiated with Buy rating at Ladenburg Thalmann By Investing.com - Investing.com South Africa
This Circle Internet Analyst Begins Coverage On A Bearish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
NovoCure stock initiated with Buy rating at Ladenburg Thalmann - Investing.com
NovoCure stock maintains Buy rating at H.C. Wainwright on positive cancer trial data - Investing.com Nigeria
New Clinical Data: Revolutionary Cancer Therapy Cuts Pancreatic Cancer Pain by 47%, Delays Opioid Use - Stock Titan
Novocure to Present Final Secondary Endpoint Data from the Phase - GuruFocus
NVCR SEC FilingsNovocure 10-K, 10-Q, 8-K Forms - Stock Titan
Novocure to Report Second Quarter 2025 Financial Results | NVCR Stock News - GuruFocus
NovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of “Moderate Buy” by Analysts - Defense World
Demystifying NovoCure: Insights From 4 Analyst Reviews - Nasdaq
NovoCure Limited's (NASDAQ:NVCR) P/S Still Appears To Be Reasonable - simplywall.st
Rhumbline Advisers Has $2.69 Million Stock Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles By Investing.com - Investing.com South Africa
Novocure’s SWOT analysis: innovative cancer therapy firm faces growth hurdles - Investing.com India
NovoCure Ltd (NVCR) Shares Up 4.08% on Jun 6 - GuruFocus
NVCR Stock Dips Despite Positive OS Data From Phase 3 PANOVA-3 Trial - TradingView
Mackenzie Financial Corp Purchases Shares of 6,820 NovoCure Limited (NASDAQ:NVCR) - Defense World
Insider Sell Alert: Frank Leonard Sells 30,196 Shares of NovoCure Ltd (NVCR) - GuruFocus
Novocure at Jefferies Conference: Expanding Horizons in Cancer Treatment - Investing.com
Ameriprise Financial Inc. Has $682,000 Position in NovoCure Limited (NASDAQ:NVCR) - Defense World
H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data - Investing.com Nigeria
NovoCure Ltd (NVCR) Shares Down 7.43% on Jun 2 - GuruFocus
NovoCure's Tumor Treating Fields Boost One-Year And Pain-Free Survival In Pancreatic Cancer Trial - Yahoo Finance
Novocure (NVCR) Gains Support for Future Launch from Promising T - GuruFocus
Novocure (NVCR) Gains Support for Future Launch from Promising Trial Outcomes | NVCR Stock News - GuruFocus
H.C. Wainwright reiterates Buy rating on NovoCure stock after ASCO data By Investing.com - Investing.com South Africa
Novocure (NVCR) Announces Positive Phase 3 Trial Results for Pancreatic Cancer Therapy | NVCR Stock News - GuruFocus
Novocure announces results from Phase 3 PANOVA-3 trial - TipRanks
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 - GuruFocus
Zai Lab and Novocure Announce Results From the Phase 3 PANOVA-3 Trial of Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Lelezard
Results From the Phase 3 PANOVA-3 Trial of Novocure's Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting | NVCR Stock News - GuruFocus
Results From the Phase 3 PANOVA-3 Trial of Novocure’s Tumor Treating Fields (TTFields) Therapy for Pancreatic Cancer to be Presented at 2025 ASCO Annual Meeting - Yahoo Finance
NovoCure Ltd (NVCR) Shares Gap Down to $18.5801 on May 30 - GuruFocus
Novocure Ltd (NVCR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.39%
자본화:
|
볼륨(24시간):